Immune Checkpoint Inhibitors – Special Topics – Special Topics: Immune Checkpoint Inhibitors (G7)
Immune checkpoint inhibitors have had a transformative impact in many oncology settings since their entry into the marketplace a little over a decade ago. Their use continues to advance into earlier lines of therapy, including the adjuvant and neoadjuvant settings, and into novel combinations with both existing and emerging agents. Combinations of PD-1 / PD-L1 checkpoint inhibitors with therapies targeting other immune checkpoints, such as LAG-3, also feature in approved and emerging regimens. This Special Topics report gives a comprehensive market forecast of current and emerging immune checkpoint inhibitors and their market trends and dynamics in a variety of oncology indications.
QUESTIONS ANSWERED
- What are the approval timelines and current landscapes for approved immune checkpoint inhibitors, and what combination strategies are being more successful?
- What is the market potential and positioning of emerging immune checkpoint inhibitors?
- What is the commercial potential of current and emerging immune checkpoint inhibitors by brand, indication, combination, and geography, and how will the market evolve over the 2022-2032 forecast period?
GEOGRAPHIES
United States, EU5, Japan.
EPIDEMIOLOGY
Drug-treated cases by brand, indication, combination type, and geography for indications for which immune checkpoint inhibitors are approved or forecast for approval.
FORECAST
10-year, annualized, drug-level sales of immune checkpoint inhibitors through 2032, segmented by indication, target, combination type, and geography.
KEY DRUGS COVERED
Currently approved agents targeting PD-1, PD-L1, CTLA-4, and LAG-3.
EMERGING THERAPIES
Phase 3 / PR.
PRODUCT DESCRIPTION
Clarivate’s Special Topics reports assess key trends in dynamic disease areas. This report offers a comprehensive market forecast of the immune checkpoint inhibitor landscape in relevant oncology indications.
Catherine E. Willoughby, Ph.D., Healthcare Research & Data Analyst, Oncology. Dr. Willoughby has more than 10 years of experience in oncology research and drug discovery. She obtained her Ph.D. at Newcastle University, where she explored novel therapeutic strategies to treat liver cancer. She was a Sara Borrell Postdoctoral Fellow at IDIBAPS-Hospital Clinic, where she investigated new treatment combinations to overcome resistance to immune checkpoint inhibitors and, more recently, was a postdoctoral fellow at IRB Barcelona, where she investigated molecular glue therapeutics to treat immune-inflammatory skin diseases. Dr. Willoughby also holds a B.Sc. (honors) in medical biochemistry with industrial experience from the University of Manchester and an M.Res. in cancer research from Newcastle University.
Rajashri Lella, M.Pharm., Associate Healthcare Research & Data Analyst, Oncology. Ms. Lella performs secondary market research, which includes patent research and pricing for major pharmaceutical markets covering multiple oncology indications. She previously worked on Clarivate’s Oncology Clinical Trial Monitor. Ms. Lella completed a master’s degree in pharmaceutical quality assurance at Manipal Academy of Higher Education in India.